Exhibitor Theater Presentations/Industry Symposia
The following company has provided an educational grant in support of this symposium: Takeda Pharmaceuticals U.S.A, Inc.
Miguel D. Regueiro, MD, FACG, Russell D. Cohen, MD, FACG, Corey A. Siegel, MD, MS
Review the evidence in support of MH as a primary goal of CD treatment; Discuss strategies to define, monitor, and achieve MH in patients with moderate-to-severe CD; Evaluate the clinical trial data and RWE surrounding the impact of available biologics on MH induction and maintenance for optimal therapeutic positioning.
Industry-sponsored satellite symposia provide additional educational opportunities for attendees. These programs are independent of the ACG 2019 Annual Scientific Meeting and Postgraduate Course programs. ACG is not the continuing medical education provider of these programs. For more information, see the company sponsor.